Media, investors, advocacy organizations and others, please contact us here.
For US healthcare professionals only
The purpose of this Travere Therapeutics Medical Affairs website is to support healthcare professionals with scientific information. This website is also a channel for US healthcare professionals to submit questions or connect with US professionals. The information provided is for educational purposes only and is not intended to promote any products. By continuing to use this site you are acknowledging that you are a US healthcare professional.
Antiproteinuric Effect of Sparsentan (SPAR) After Maximized Irbesartan (IRB) in Patients (Pts) With Focal Segmental Glomerulosclerosis (FSGS) in the DUPLEX Open-Label Extension (OLE)
You are now leaving the Travere Therapeutics Medical Affairs website. The site you are accessing is maintained by a third party over whom Travere Therapeutics has no control. Travere Therapeutics does not review, approve, or necessarily endorse viewpoints, inferences, or conclusions stated in or implied by the content of this site. Travere Therapeutics is not responsible for third-party content or the consequences of your use thereof.